Literature DB >> 17351984

Corneal epithelium as a platform for secretion of transgene products after transfection with liposomal gene eyedrops.

Elisa Toropainen1, Margit Hornof, Kai Kaarniranta, Pinja Johansson, Arto Urtti.   

Abstract

BACKGROUND: The first objective of the study was to evaluate the transfection of corneal epithelium with non-viral vectors to secrete transgene products into the tear fluid and aqueous humor. The second goal was to evaluate the differentiated corneal epithelial cell culture for transfection studies.
METHODS: The human corneal epithelial (HCE) cell line was cultured to different stages of differentiation and transfected with complexes of pCMV-SEAP2 with DOTAP/DOPE, DOTAP/DOPE/protamine sulfate (PS) and polyethylenimine (PEI). The complexes of DOTAP/DOPE with plasmid (CMV-SEAP2 or pCMV-Luc4) were subsequently applied topically to the rabbit eyes. Secreted alkaline phosphatase (SEAP) was analyzed using chemiluminescent assay. Luciferase (Luc) was detected at the mRNA level in cornea and conjunctiva using a qRT-PCR.
RESULTS: The transfection levels decreased with differentiation of HCE cells. PEI was effective in transfecting both the dividing and partly differentiated cells, but ineffective in differentiated cells. DOTAP/DOPE showed high activity in differentiated cell cultures, while added PS did not improve transfection. Significant SEAP expression was observed for three days after in vivo transfection in the tear fluid and aqueous humor. The luciferase mRNA was found both in the cornea and conjunctiva. The rates of SEAP secretion from both the basolateral side of differentiated HCE cells and cornea in vivo were within the same range.
CONCLUSIONS: Corneal epithelium can be transfected topically to secrete gene products to the tear fluid and aqueous humor. The differentiated HCE model is a useful tool in the evaluation of non-viral carriers for corneal transfection. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351984     DOI: 10.1002/jgm.1011

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

Review 1.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

Review 2.  Corneal gene therapy: basic science and translational perspective.

Authors:  Rajiv R Mohan; Jason T Rodier; Ajay Sharma
Journal:  Ocul Surf       Date:  2013-02-13       Impact factor: 5.033

3.  Swarms of chemically modified antiviral siRNA targeting herpes simplex virus infection in human corneal epithelial cells.

Authors:  Kiira Kalke; Liisa M Lund; Marie C Nyman; Alesia A Levanova; Arto Urtti; Minna M Poranen; Veijo Hukkanen; Henrik Paavilainen
Journal:  PLoS Pathog       Date:  2022-07-06       Impact factor: 7.464

4.  Gene expression analysis in SV-40 immortalized human corneal epithelial cells cultured with an air-liquid interface.

Authors:  Dario Greco; Kati-Sisko Vellonen; Helen C Turner; Marika Häkli; Timo Tervo; Petri Auvinen; J Mario Wolosin; Arto Urtti
Journal:  Mol Vis       Date:  2010-10-15       Impact factor: 2.367

5.  Effluxing ABC transporters in human corneal epithelium.

Authors:  Kati-Sisko Vellonen; Eliisa Mannermaa; Helen Turner; Marika Häkli; J Mario Wolosin; Timo Tervo; Paavo Honkakoski; Arto Urtti
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

Review 6.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

Review 7.  Gene therapy in keratoconus.

Authors:  Mahgol Farjadnia; Mohammad Naderan; Mehrdad Mohammadpour
Journal:  Oman J Ophthalmol       Date:  2015 Jan-Apr

Review 8.  Polysaccharides in Ocular Drug Delivery.

Authors:  Natallia Dubashynskaya; Daria Poshina; Sergei Raik; Arto Urtti; Yury A Skorik
Journal:  Pharmaceutics       Date:  2019-12-24       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.